Studies on the effect of 9-(R, S)-(2,3-dihydroxypropyl)adenine on tick-borne encephalitis virus.
Peroral treatment with 9-(R, S)-(2,3-dihydroxypropyl) adenine did not protect mice infected with tick-borne encephalitis (TBE) viruses (strains Hypr and Ir13) when the drug was administered at the time or infection and/or up to day 2 after infection. The analogue inhibited the haemagglutination activity of the Skalica strain in vitro.
D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D004669:Encephalitis Viruses, Tick-Borne / Q000187:drug effects*; D004675:Encephalitis, Tick-Borne / Q000188:drug therapy*; D006387:Hemagglutination, Viral / Q000187:drug effects; D051379:Mice
D000998:Antiviral Agents; C016391:9-(2,3-dihydroxypropyl)adenine; D000225:Adenine